Adrenal incidentalomas have quietly become one of the more vexing management challenges in contemporary urological practice. Defined as adrenal masses discovered unexpectedly during imaging performed for a completely unrelated clinical reason, these lesions now surface with striking regularity — a direct consequence of the widespread use of high-resolution cross-sectional imaging in routine medicine. Autopsy data have long suggested a prevalence of around 1–8%, and population-based imaging series confirm that this figure rises steadily with age, reaching as high as 7% in patients over 70.
The core dilemma is straightforward to state but genuinely difficult to resolve: the overwhelming majority of incidentally found adrenal masses are benign and clinically silent, yet a meaningful minority harbor functional hormonal activity, malignant potential, or both. Mismanaging either category carries real consequences — unnecessary surgery on one end, missed cancer or uncontrolled hormonal excess on the other. As the peer-reviewed scholarship in this space has grown richer, Urology Journal has emerged as one of the key venues in which clinicians and researchers have worked through the evidence, refining the thresholds that separate a lesion best left under observation from one that demands surgical intervention.
Understanding Adrenal Incidentalomas: The Scope of the Problem
Adrenal incidentalomas are not a clinical curiosity — they are a common finding. Cross-sectional imaging studies estimate that roughly 4–7% of adults undergoing abdominal computed tomography (CT) for unrelated indications will have an incidental adrenal finding. The histological landscape of these lesions is dominated by benign cortical adenomas, which account for approximately 80% of all cases. The remaining 20% span a wide spectrum: myelolipomas, simple cysts, ganglioneuromas, adrenocortical carcinoma, pheochromocytoma, and metastatic deposits, among others.
What makes the management question particularly layered is that a benign appearance on imaging does not preclude subtle hormonal activity. Studies consistently show that a subset of seemingly nonfunctioning adenomas produce autonomous cortisol secretion at levels insufficient to cause the full clinical picture of Cushing’s syndrome but significant enough to elevate cardiovascular and metabolic risk. This entity — now widely described in the literature as mild autonomous cortisol secretion (MACS) — has reshaped how clinicians approach the hormonal workup of every newly discovered adrenal mass.
While adrenal disease sits at the intersection of endocrinology, oncology, and surgery, it is the urologist who most frequently performs adrenalectomy and who is often among the first specialists to evaluate a newly discovered mass identified during broader abdominal imaging. Urology Journal research reflects this multidisciplinary reality. Publications in the journal have consistently examined adrenal incidentalomas not only through the lens of surgical technique but also through radiological characterization, biochemical evaluation, oncological outcomes, and long-term follow-up — providing a comprehensive resource for the clinician trying to navigate these cases in a systematic way.
Radiological Characterization: The First Step in Risk Stratification
Unenhanced CT as the Primary Discriminator
The unenhanced CT scan is the cornerstone of initial radiological evaluation for any incidentally discovered adrenal mass. Hounsfield unit (HU) attenuation measured on non-contrast CT remains the single most reliable imaging parameter for distinguishing lipid-rich adenomas from potentially malignant lesions. A threshold of 10 HU or below carries high sensitivity and specificity for a benign lipid-rich adenoma, largely eliminating the need for further radiological workup in those cases.
Urology Journal has highlighted studies that support this threshold as a robust first-line discriminator, while also acknowledging its limitations: approximately 30% of pathologically confirmed adenomas are lipid-poor and therefore exceed 10 HU on unenhanced CT. A significant number of genuinely benign lesions will still require contrast-enhanced imaging for definitive characterization.
Contrast-Enhanced CT and Washout Analysis
For lesions with unenhanced attenuation above 10 HU, adrenal-protocol contrast-enhanced CT with washout calculation provides the next level of discrimination. Two validated parameters are routinely used to assess contrast retention. The table below summarizes the thresholds that have been consistently supported in the urological and endocrinological literature, including studies referenced in Urology Journal:
| Washout Measure | Formula | Threshold Suggesting Adenoma |
|---|---|---|
| Absolute Percentage Washout (APW) | (Enhanced HU − Delayed HU) / (Enhanced HU − Unenhanced HU) × 100 | ≥ 60% |
| Relative Percentage Washout (RPW) | (Enhanced HU − Delayed HU) / Enhanced HU × 100 | ≥ 40% |
Lesions meeting these washout criteria are reliably classified as adenomas with high diagnostic accuracy. Those falling below the thresholds — particularly larger masses with irregular borders, heterogeneous enhancement, or calcification — warrant further investigation through additional imaging modalities such as MRI or FDG-PET/CT, or through surgical excision when clinical suspicion for malignancy is high.
Hormonal Evaluation: Ruling Out Functional Disease
Regardless of how reassuring the imaging appearance may be, every patient with a newly discovered adrenal incidentaloma should undergo biochemical screening to exclude clinically relevant hormonal excess. Urology Journal research underscores that functional evaluation is not optional — it is the established clinical standard. The following conditions must be systematically assessed before any management decision is made:
- Autonomous cortisol excess: Evaluated using the overnight 1 mg dexamethasone suppression test (DST). A post-DST cortisol above 50 nmol/L (1.8 µg/dL) warrants further evaluation; levels above 138 nmol/L (5 µg/dL) indicate overt autonomous secretion.
- Pheochromocytoma: Assessed through plasma free metanephrines or 24-hour urinary fractionated metanephrines. This diagnosis must be excluded before any surgical intervention, regardless of the primary operative indication.
- Primary aldosteronism: Screened using the aldosterone-to-renin ratio (ARR) in all hypertensive patients and in normotensive patients with spontaneous or diuretic-exacerbated hypokalemia.
- Sex steroid or precursor excess: Considered in cases where clinical features such as virilization or feminization are present, or where adrenocortical carcinoma is suspected on imaging grounds.
This panel of assessments forms the minimum standard prior to any management decision. Omitting any single element risks misclassifying a functionally active lesion as benign — a clinical error with potentially serious long-term consequences for the patient.
The Monitoring Pathway: Evidence on Surveillance Protocols
For the large proportion of adrenal incidentalomas that are small, imaging-benign, and hormonally silent on initial evaluation, a conservative monitoring approach is both appropriate and well supported by the published evidence. Urology Journal has reviewed and published data clarifying the optimal frequency, duration, and imaging modality of such follow-up. The table below outlines the key characteristics that support a surveillance-first management approach:
| Characteristic | Favorable for Surveillance |
|---|---|
| Maximum diameter on initial imaging | Less than 4 cm |
| Unenhanced CT attenuation | 10 HU or below (lipid-rich adenoma profile) |
| Contrast washout (when performed) | APW ≥ 60% or RPW ≥ 40% |
| Hormonal profile | No evidence of excess across all four evaluated domains |
| Growth rate on repeat imaging | Less than 1 cm increase over 12 months |
| Imaging morphology | Homogeneous, smooth-bordered, no necrosis or internal calcification |
For patients entering the surveillance pathway, the standard recommendation supported by published evidence includes repeat cross-sectional imaging at 6 to 12 months after initial discovery, followed by annual imaging for up to four years if the lesion remains stable. Hormonal reassessment — particularly the dexamethasone suppression test — is similarly recommended on an annual basis for approximately four to five years, given the possibility that subtle cortisol excess may emerge or become clinically apparent over time. Urology Journal research consistently emphasizes that the intensity and duration of surveillance should be individualized rather than applied mechanically: a 35-year-old with a clearly benign 2 cm adenoma requires a different approach than a 65-year-old with borderline imaging characteristics and multiple cardiovascular comorbidities.
Surgical Indications: When the Evidence Points Toward Operation
Several scenarios represent clear surgical indications that are consistently endorsed across the published literature and reflected in research discussed in Urology Journal. The following list covers the situations where the weight of evidence — regardless of the specific guideline consulted — points unambiguously toward adrenalectomy for appropriate surgical candidates:
- Confirmed pheochromocytoma: All biochemically verified pheochromocytomas should be surgically removed. The risk of life-threatening hypertensive crisis, cardiac arrhythmia, and progressive tumor growth makes conservative management indefensible in fit patients.
- Confirmed or highly suspected adrenocortical carcinoma (ACC): Masses with imaging features suggesting malignancy — high HU on unenhanced CT, irregular borders, heterogeneous enhancement, poor washout, size above 4 cm — require excision. Complete surgical resection remains the only potentially curative treatment for ACC.
- Primary aldosteronism with confirmed unilateral disease: In patients with lateralized aldosterone hypersecretion confirmed on adrenal vein sampling, unilateral adrenalectomy offers the prospect of biochemical cure and frequently achieves resolution or significant improvement of hypertension.
- Overt Cushing’s syndrome attributable to unilateral adrenal disease: When florid clinical and biochemical hypercortisolism is confirmed and the responsible lesion is clearly unilateral, adrenalectomy is the treatment of choice.
- Size exceeding 4 cm with indeterminate imaging features: Even in the absence of histologically confirmed malignancy, the elevated a priori probability of adrenocortical carcinoma in lesions above this size threshold justifies surgery in patients with acceptable operative risk.
These indications are not disputed in the contemporary literature. Where genuine clinical debate persists — and where Urology Journal research has engaged most substantively — is in the gray area of mild autonomous cortisol secretion.
The Gray Zone: Mild Autonomous Cortisol Secretion
MACS, defined by a post-DST cortisol between 51 and 138 nmol/L without the clinical stigmata of overt Cushing’s syndrome, occupies an uncomfortable middle ground that neither a reflexive surgical recommendation nor an automatic decision to observe serves well. The available evidence — increasingly discussed in Urology Journal publications — suggests that MACS is not clinically neutral. Patients with this degree of subclinical cortisol excess demonstrate higher rates of hypertension, type 2 diabetes, dyslipidemia, osteoporosis, and adverse cardiovascular events compared with those who have truly nonfunctioning adenomas.
Several prospective and retrospective studies have demonstrated that adrenalectomy in carefully selected MACS patients leads to meaningful improvements in metabolic parameters and may reduce long-term cardiovascular risk. Urology Journal research indicates that the decision to operate in this group should hinge on a combination of factors: the patient’s age and overall fitness for surgery, the degree of autonomous secretion on biochemical testing, the burden and controllability of metabolic comorbidities, and the patient’s own informed preference after a thorough discussion of the available evidence. In younger patients with poorly controlled hypertension, diabetes, or progressive osteoporosis plausibly attributable to cortisol excess, the balance tends to favor surgery. In older, more frail patients with well-managed metabolic disease, continued surveillance remains a defensible and reasonable strategy.
Surgical Technique: Minimally Invasive Versus Open Adrenalectomy
When surgery is the agreed-upon course of action, the preferred approach for the majority of adrenal incidentalomas — provided malignancy is not strongly suspected — is minimally invasive adrenalectomy. Urology Journal has published multiple series, technical notes, and comparative reviews addressing operative approach, perioperative outcomes, and the patient- and lesion-specific factors that influence technique selection.
Laparoscopic adrenalectomy, performed either transperitoneally or retroperitoneoscopically, has become the standard of care for benign and functional adrenal masses below 8–10 cm in diameter. Comparative outcome data consistently demonstrate shorter hospital stays, reduced intraoperative blood loss, faster postoperative recovery, and comparable oncological control for appropriately selected cases. The retroperitoneoscopic approach, in particular, has gained considerable traction in high-volume referral centers: by avoiding entry into the peritoneal cavity altogether, it reduces the risk of visceral injury and limits the adhesion formation that complicates subsequent abdominal surgery.
Open adrenalectomy remains the necessary approach for large tumors — typically above 8–10 cm — cases where adrenocortical carcinoma is suspected or confirmed, and situations in which laparoscopic exposure is anatomically inadequate due to prior surgery or tumor complexity. When ACC is the operative indication, sound oncological principles demand open resection with wide margins; the oncological risk of tumor rupture or positive margins in minimally invasive ACC resection is a recognized concern in the surgical literature.
Postoperative Monitoring and Long-Term Follow-Up
Surgery does not conclude the clinical story for many patients managed for adrenal incidentalomas. Those who have undergone adrenalectomy for MACS or overt autonomous cortisol secretion require careful postoperative hormonal monitoring. The contralateral adrenal — suppressed by prolonged excess cortisol production from the resected gland — may take weeks to months to resume adequate function, placing patients at genuine risk for adrenal insufficiency during this recovery interval. Perioperative glucocorticoid replacement is essential, with dose tapering guided by serial cortisol measurements and clinical assessment.
For patients who remain on active surveillance after initial evaluation, the follow-up framework is well defined, though the optimal duration before discharge from formal monitoring continues to generate discussion in the literature. Most published evidence and expert guidance supports discontinuing routine imaging surveillance after four to five years of radiological stability. Annual hormonal assessment — centered on the dexamethasone suppression test — should continue for a comparable period, given the documented possibility of progressive cortisol autonomy developing over time in lesions that initially appear nonfunctioning.
Conclusion
Adrenal incidentalomas represent a genuine and growing clinical challenge precisely because their often-unremarkable surface presentation can conceal meaningful hormonal activity, malignant pathology, or both. The evidence assembled through years of research published and critically reviewed in Urology Journal provides clinicians with a structured, defensible framework: rigorous radiological characterization anchored by unenhanced CT attenuation and contrast washout analysis, systematic hormonal evaluation across four distinct domains, and a clear decision pathway that distinguishes the lesions requiring surgical intervention from those best managed through careful, time-limited observation.
What the cumulative literature makes unmistakably clear is that neither reflexive surgery nor passive, imaging-only follow-up serves patients optimally. The evidence strongly supports a nuanced, individualized strategy — one that weighs lesion size, imaging phenotype, hormonal status, patient comorbidities, and operative risk in equal measure. As new prospective data on MACS outcomes, expanded experience with retroperitoneoscopic adrenalectomy, and advances in adrenal imaging continue to emerge, Urology Journal research remains an important part of the evidence base that practicing urologists and endocrine surgeons rely on when making decisions that carry real and lasting consequences for their patients.
